Recommendations for evaluation and management of bone disease in HIV.
about
Human Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining ConditionsPerspectives on menopause and women with HIVBone health in HIV and hepatitis B or C infectionsHIV infection and bone disease.What's new for antiretroviral treatment in women with HIVHow to predict the risk of fracture in HIV?Bone loss in HIV: a contemporary review.Antiretroviral therapy induces a rapid increase in bone resorption that is positively associated with the magnitude of immune reconstitution in HIV infectionThe protease inhibitors and HIV-associated bone loss.Tenofovir and bone health.Usefulness of calcaneal quantitative ultrasound stiffness for the evaluation of bone health in HIV-1-infected subjects: comparison with dual X-ray absorptiometryAdverse bone health among children and adolescents growing up with HIV.Bone Disease in HIV: Recommendations for Screening and Management in the Older Patient.Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults.Management of bone mineral density in HIV-infected patients.Hepatitis C virus coinfection as a risk factor for osteoporosis and fracture.Bone Loss in HIV Infection.Protecting bone in long-term HIV positive patients receiving antiretrovirals.Physiological and pathophysiological bone turnover - role of the immune system.Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort.HIV and Bone Complications: Understudied Populations and New Management Strategies.Heel quantitative ultrasound in HIV-infected patients: a cross-sectional study.Fracture Prediction With Modified-FRAX in Older HIV-Infected and Uninfected Men.Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial.Trabecular bone score (TBS) is associated with sub-clinical vertebral fractures in HIV-infected patients.Body composition in HIV-infected patients receiving highly active antiretroviral therapy.A Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-induced Bone Loss in Treatment-naive HIV-infected Patients: A Phase IIb Trial.Improvement of BMD after Switching from Lopinavir/R Plus Two Nucleos(T)ide Reverse Transcriptase Inhibitors to Lopinavir/R Plus Lamivudine: OLE-LIP Substudy.Iatrogenic Cushing's syndrome and osteoporosis due to an interaction between fluticasone and ritonavir.Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors.Endocrinological aspects of HIV infection.Cost-effective osteoporosis treatment thresholds for people living with HIV infection in Greece.T-cell receptor activator of nuclear factor-κB ligand/osteoprotegerin imbalance is associated with HIV-induced bone loss in patients with higher CD4+ T-cell counts.Aging in HIV-Infected Subjects: A New Scenario and a New View.Mexican patients with HIV have a high prevalence of vertebral fractures.Continued Interest and Controversy: Vitamin D in HIV.International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UKThe Hidden Burden of Fractures in People Living With HIV
P2860
Q26740117-92FF0458-30F0-464D-B7A0-D4E868092B37Q26772852-2099B592-A12C-4E15-8C84-EFB82986252DQ30238946-F256061F-9335-4682-9BAD-A2A847868906Q30249771-E597BC0A-3ED5-4C95-A242-7A21EC76F4BAQ30391322-584E1335-553C-4B8D-9790-DC3236EC8680Q33588713-069BC9D0-CCD1-464F-9310-F463B6218746Q36330955-16EBCF7C-9AC1-4457-8FA6-E16E6579708EQ36462148-468B106D-7426-4E4D-995C-505C4BE514D2Q36818259-F96AD5F4-B7FA-4D49-80CA-28922644F2F3Q36833961-6D38A1E0-384D-4AED-B5CD-C6325B78FC16Q36981208-711D32CB-DD8F-4113-A2A4-2CDBFCEBFF16Q37098360-8FFD8D5A-A50D-497E-9B98-FAEECF86C08AQ38540406-66A35D03-18CE-4E81-8BD3-4FE027783619Q38661064-0F303DE2-EF03-49EB-85CD-1403E4B3A25DQ38711437-C01C0028-DDD0-4938-8AB3-4C6431B19064Q38738823-118CE14C-D225-44C8-A0ED-B9607E634DA8Q38835028-3E1368AA-E4F2-4613-AF63-E1784F79578AQ38836871-B8FE8D63-0BF5-4549-985F-94FE1C3B8897Q38867785-DCAD6912-A12D-4E97-BF16-D3DC2D28A456Q38915191-1EA1A4C9-4B3E-4255-9BD6-DDD8A2A696E1Q38978479-26819CD1-0397-4F23-9215-B8DC4EA09EB1Q39357708-14DB4E22-0EE8-49C6-B2E1-6D1C6AF83E52Q39898279-48033E80-FE0F-4BC4-85DD-E74B8222C3DBQ40158081-A8276511-378C-49B5-AAC5-03989B1F2CCBQ40319693-F78840B6-B827-4769-AF53-1BFF1A92D7E0Q40511639-D3906565-8B0A-4130-894B-7654AD49AB09Q40668927-B3671696-F7BD-4735-A8F2-A4A62536E14AQ40695106-CE497EE4-28EB-4046-BE51-8CC22E9E6470Q40931267-44F71F46-EFAE-4EB8-A487-F07B60B5EAF4Q45324519-3C0FCA71-C96B-4863-86F9-BA0135B9BEA6Q47219853-9F5D2E58-D42C-44A6-8B5D-7DC068E6FAB2Q49334645-8CE65D5C-E274-4CF2-B7DC-B3BEE5B82711Q50051644-74ECD2D3-EFAB-4DDC-8156-597DFDA70942Q50072732-70E4E2A6-9AEF-4973-A2C8-5353215C7445Q54222374-F6C4B6AB-71D5-4135-8144-CB1384E43286Q54224147-E1F51B5B-8EDF-448D-AD69-25E056E5A9ADQ56762706-74533F88-0F77-4F03-9BB0-1B574336ADD3Q57143538-312908D7-358E-4498-B7F0-D63789F22DCB
P2860
Recommendations for evaluation and management of bone disease in HIV.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Recommendations for evaluation and management of bone disease in HIV.
@ast
Recommendations for evaluation and management of bone disease in HIV.
@en
type
label
Recommendations for evaluation and management of bone disease in HIV.
@ast
Recommendations for evaluation and management of bone disease in HIV.
@en
prefLabel
Recommendations for evaluation and management of bone disease in HIV.
@ast
Recommendations for evaluation and management of bone disease in HIV.
@en
P2093
P2860
P50
P356
P1476
Recommendations for evaluation and management of bone disease in HIV.
@en
P2093
Boris Renjifo
Fabio Vescini
Marco Borderi
Michael T Yin
Todd T Brown
P2860
P304
P356
10.1093/CID/CIV010
P407
P577
2015-01-21T00:00:00Z